Atturos is a fast growing clinical diagnostics company developing molecular diagnostic tests to support better patient decisions. Currently focusing on the identification of serum protein biomarkers, Atturos uses cutting edge technology in collaboration with key clinical consortia and big pharma.  

What we do

Atturos is a University College Dublin (UCD) spin out company founded in December 2016 specifically with the intention of commercialising the OCProDx test. Atturos is a company based on sophisticated science with patient well-being at its core. The first product we are developing is a simple blood test to determine whether or not diagnosed prostate cancer is confined to the prostate. With this information, patients can have an informed role in their choice of treatment, including the opportunity of patient monitoring via active surveillance. This aims to prevent unnecessary over treatment of a disease that most patients will not die from. The test itself is performed on a robust clinical platform using advanced proteomics methods and state-of-the-art equipment. Atturos has a highly experienced and committed initial leadership team who have the support of a wide network of commercial, clinical and scientific advisors. 

Patient driven molecular diagnostics

How we do it

Excellent science is at the heart of everything we do at Atturos. Using state-of-the-art equipment and advanced proteomics methods, we are consistently developing (and improving) our methods to identify biomarkers for various diseases. Mass spectrometry has proven to be a robust platform, and the best statistical approaches have been used to build an established clinical laboratory. Targeted MS analysis using Multiple Reaction Monitoring (MRM) allows us to detect and quantify ultra-low protein concentrations. This method also has the advantages of high specificity, sensitivity, multiplexing capability, and precision over other commonly used molecular diagnostic methods. The end result of this is an easy to interpret score to help clinicians and patients make informed decisions about their healthcare. The Atturos team have spent many years researching biomarker discovery and are committed to converting their efforts into clinically utilised tests. 

Sophisticated science generating robust results

Our vision

Our intention, subject to continued robust validation, is to deliver the OCProDx test to routine practice to improve clinical and patient decisions in prostate cancer. Atturos plan to commercialise the OCProDx test in late 2022. Our goal is to give patients and clinicians clearer information to help them make guided treatment decisions.

Our longer term vision is to integrate molecular diagnostics into decision making tools to improve the health and quality of life patients while also increasing the cost-effectiveness of healthcare systems. Atturos has ambitious plans for rapid development, growth and internationalisation, and already has a pipeline of other tests in research development.

The existing management team has experience with commercialisation and ambitions to be an integral part of the evolving senior management group of the company while at the same time recognising the need to identify and engage senior experienced executives. The travel and networking associated with the feasibility study will provide an important opportunity to identify such individuals.

Better decisions based on solid science



to help patients make better decisions


Atturos is proud to collaborate with...